BioHarvest Sciences Inc. (CNVCF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BioHarvest Sciences Inc. (CNVCF) with AI Score 66/100 (Buy). BioHarvest Sciences Inc. focuses on nutraceutical super fruits and cannabis verticals, utilizing its plant cell growth technology to produce active secondary metabolites. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026BioHarvest Sciences Inc. (CNVCF) Healthcare & Pipeline Overview
BioHarvest Sciences Inc. operates in the nutraceutical and cannabis sectors, leveraging its proprietary plant cell growth technology to produce and market Vinia, a red grape powder nutraceutical, and medical cannabis. With a focus on international markets, the company aims to deliver plant-based solutions without traditional agricultural methods.
Investment Thesis
BioHarvest Sciences Inc. presents a speculative investment opportunity in the nutraceutical and cannabis sectors, driven by its innovative Bioplant technology. The company's potential lies in its ability to efficiently produce plant-based compounds, offering a sustainable alternative to traditional agriculture. Key value drivers include the growth of Vinia sales, expansion into new markets, and the development of novel cannabis-based products. The company's negative P/E ratio of -17.80 and a negative profit margin of -40.9% indicate it is not yet profitable. A beta of 1.49 suggests higher volatility than the market. Upcoming catalysts include potential regulatory approvals for its cannabis products and expansion of its distribution network. However, investors should be aware of the risks associated with operating in the highly regulated cannabis industry and the challenges of scaling production and marketing efforts.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.11B reflects its position as a smaller player in the nutraceutical and cannabis markets.
- Negative P/E Ratio of -17.80 indicates the company is currently not profitable, requiring careful monitoring of its path to profitability.
- Gross Margin of 56.7% suggests strong pricing power and efficient production of its Vinia product.
- Beta of 1.49 indicates higher volatility compared to the overall market, which may appeal to risk-tolerant investors.
- No Dividend Yield reflects the company's focus on reinvesting earnings for growth rather than returning capital to shareholders.
Competitors & Peers
Strengths
- Proprietary Bioplant technology.
- Established Vinia brand.
- Expertise in cannabis cultivation.
- International operations.
Weaknesses
- Limited product portfolio.
- Negative profitability.
- Small market capitalization.
- Reliance on regulatory approvals.
Catalysts
- Upcoming: Potential regulatory approvals for cannabis products in new markets.
- Ongoing: Expansion of Vinia distribution network through strategic partnerships.
- Ongoing: Development of new cannabis-based products with unique cannabinoid profiles.
- Ongoing: Continued innovation in Bioplant technology to improve efficiency and scalability.
Risks
- Potential: Competition from established players in the nutraceutical and cannabis industries.
- Potential: Regulatory changes impacting the cannabis market.
- Potential: Fluctuations in cannabis prices affecting profitability.
- Ongoing: Challenges in scaling production and marketing efforts.
- Ongoing: Dependence on regulatory approvals for cannabis products.
Growth Opportunities
- Expansion of Vinia Sales: BioHarvest Sciences can increase Vinia sales through targeted marketing campaigns and expansion into new geographic markets. The global nutraceutical market is estimated to reach $441.7 billion by 2026, offering a substantial opportunity for growth. By focusing on e-commerce channels and strategic partnerships with retailers, the company can reach a wider customer base and drive revenue growth. Timeline: Ongoing.
- Development of Novel Cannabis Products: The company can leverage its Bioplant technology to develop novel cannabis-based products with unique cannabinoid profiles. The global medical cannabis market is projected to reach $55.8 billion by 2026. By focusing on research and development, BioHarvest Sciences can create differentiated products that address specific medical needs and capture a share of this growing market. Timeline: Ongoing.
- Strategic Partnerships: Forming strategic partnerships with established players in the nutraceutical and cannabis industries can accelerate growth and expand market reach. By partnering with distributors, retailers, and research institutions, BioHarvest Sciences can leverage their expertise and resources to commercialize its products more effectively. Timeline: Ongoing.
- Regulatory Approvals: Obtaining regulatory approvals for its cannabis products in key markets can unlock significant growth opportunities. As more countries and regions legalize medical and recreational cannabis, BioHarvest Sciences can capitalize on these opportunities by securing the necessary licenses and permits to operate in these markets. Timeline: Upcoming.
- Technological Innovation: Continued investment in research and development to further enhance its Bioplant technology can create a sustainable competitive advantage. By improving the efficiency and scalability of its production process, BioHarvest Sciences can reduce costs, increase yields, and develop new plant-based products. Timeline: Ongoing.
Opportunities
- Expansion into new geographic markets.
- Development of novel cannabis products.
- Strategic partnerships.
- Increasing legalization of cannabis.
Threats
- Competition from established players.
- Regulatory changes.
- Fluctuations in cannabis prices.
- Economic downturn.
Competitive Advantages
- Proprietary Bioplant technology for efficient plant cell growth.
- Patents protecting its technology and products.
- Established brand recognition for Vinia in the nutraceutical market.
- Expertise in cannabis cultivation and extraction.
About CNVCF
BioHarvest Sciences Inc. is a biotechnology company focused on developing and commercializing plant-based products using its proprietary plant cell growth (Bioplant) technology. Founded with the vision of producing high-value plant-based compounds sustainably and efficiently, the company has evolved into a player in both the nutraceutical and cannabis industries. Its core technology allows for the production of active secondary metabolites without the need to grow the entire plant, offering a more controlled and environmentally friendly approach. The company's flagship product, Vinia, is a red grape powder nutraceutical marketed for its antioxidant properties and potential cardiovascular benefits. Vinia is designed to deliver the health benefits of red wine without the alcohol or sugar. In addition to Vinia, BioHarvest Sciences is involved in the development and production of medical cannabis, leveraging its Bioplant technology to cultivate cannabis cells and extract valuable cannabinoids. The company operates internationally, with a focus on markets where nutraceuticals and medical cannabis are legal and regulated. BioHarvest Sciences is based in Vancouver, Canada, and has operations in Israel, where much of its research and development takes place. The company aims to expand its product portfolio and market reach through continued innovation and strategic partnerships.
What They Do
- Develops plant cell growth technology to produce active compounds.
- Manufactures and markets Vinia, a red grape powder nutraceutical.
- Cultivates cannabis cells for medical cannabis production.
- Offers plant-based solutions without traditional agriculture.
- Focuses on nutraceutical and cannabis verticals.
- Operates internationally, including Israel and Canada.
Business Model
- Produces plant-based compounds using proprietary Bioplant technology.
- Sells Vinia directly to consumers and through retailers.
- Develops and commercializes medical cannabis products.
- Generates revenue through product sales and licensing agreements.
Industry Context
BioHarvest Sciences Inc. operates within the rapidly evolving nutraceutical and cannabis industries. The nutraceutical market is driven by increasing consumer interest in health and wellness, with a global market size estimated to reach hundreds of billions of dollars. The cannabis industry is experiencing significant growth due to increasing legalization and acceptance of medical and recreational cannabis. BioHarvest Sciences competes with other nutraceutical companies and cannabis producers, including ADOIF (Advanz Pharma Corp), AMEUF (Amneal Pharmaceuticals Inc), COPHF (CorpHQ Inc), CSAMF (Cascadia Acquisition Corp), and EOFBY (Evolus Inc). The company's Bioplant technology offers a potential competitive advantage by providing a more sustainable and efficient production method.
Key Customers
- Health-conscious consumers seeking natural supplements.
- Patients using medical cannabis for therapeutic purposes.
- Retailers and distributors of nutraceutical and cannabis products.
- Pharmaceutical companies interested in plant-based ingredients.
Financials
Chart & Info
BioHarvest Sciences Inc. (CNVCF) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows Of Monday
· Aug 12, 2019
-
Stocks That Fell Through 52-Week Lows Wednesday
· Aug 7, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CNVCF.
Price Targets
Wall Street price target analysis for CNVCF.
MoonshotScore
What does this score mean?
The MoonshotScore rates CNVCF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Ilan Sobel
CEO
Ilan Sobel brings extensive experience in the pharmaceutical and consumer goods industries to his role as CEO of BioHarvest Sciences Inc. His career spans various leadership positions, including roles in marketing, sales, and business development. He has a proven track record of driving growth and innovation in both established companies and startups. Sobel's background includes a strong focus on strategic planning, market analysis, and product commercialization. He is known for his ability to build high-performing teams and execute complex projects.
Track Record: Under Ilan Sobel's leadership, BioHarvest Sciences has focused on expanding its Vinia product line and advancing its cannabis program. Key achievements include securing partnerships for distribution and increasing brand awareness. Sobel has overseen the company's efforts to optimize its Bioplant technology and develop new applications for its platform. He has also guided the company through regulatory challenges and market fluctuations.
CNVCF OTC Market Information
The OTC Other tier represents the lowest tier of over-the-counter (OTC) stocks. Companies in this tier often have limited financial disclosure and may not meet minimum listing requirements of major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries significant risks due to the potential for lack of transparency and regulatory oversight. These companies may not be required to file regular reports with the SEC, making it difficult for investors to assess their financial health and business prospects. Investors should exercise extreme caution and conduct thorough due diligence before investing in OTC Other stocks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure due to OTC listing.
- Lower liquidity and higher price volatility.
- Potential for fraud or manipulation.
- Lack of regulatory oversight.
- Difficulty in obtaining reliable information.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with the OTC market.
- Consult with a financial advisor.
- Check for any regulatory actions or legal disputes.
- Established Vinia brand in the nutraceutical market.
- Proprietary Bioplant technology.
- International operations.
- Experienced management team.
Common Questions About CNVCF
What does BioHarvest Sciences Inc. do?
BioHarvest Sciences Inc. is a biotechnology company that leverages its proprietary Bioplant technology to produce plant-based compounds without traditional agriculture. The company focuses on the nutraceutical and cannabis sectors, manufacturing and marketing Vinia, a red grape powder nutraceutical, and developing medical cannabis products. Its core technology allows for the efficient and sustainable production of active secondary metabolites, offering a competitive advantage in the market. BioHarvest Sciences operates internationally, with a focus on markets where nutraceuticals and medical cannabis are legal and regulated.
What do analysts say about CNVCF stock?
AI analysis is pending for CNVCF stock. Generally, analysts will assess BioHarvest Sciences Inc.'s potential based on its Bioplant technology, market opportunities in the nutraceutical and cannabis sectors, and financial performance. Key valuation metrics include revenue growth, gross margin, and profitability. Growth considerations include the company's ability to expand its product portfolio, enter new markets, and secure regulatory approvals. Investors should conduct their own research and consult with a financial advisor before making any investment decisions.
What are the main risks for CNVCF?
BioHarvest Sciences Inc. faces several risks, including competition from established players in the nutraceutical and cannabis industries, regulatory changes impacting the cannabis market, and fluctuations in cannabis prices. The company's reliance on regulatory approvals for its cannabis products poses a significant risk, as delays or denials could negatively impact its growth prospects. Additionally, challenges in scaling production and marketing efforts could hinder its ability to achieve profitability. Investors should carefully consider these risks before investing in CNVCF.
What are the key factors to evaluate for CNVCF?
BioHarvest Sciences Inc. (CNVCF) currently holds an AI score of 66/100, indicating moderate score. Key strength: Proprietary Bioplant technology.. Primary risk to monitor: Potential: Competition from established players in the nutraceutical and cannabis industries.. This is not financial advice.
How frequently does CNVCF data refresh on this page?
CNVCF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CNVCF's recent stock price performance?
Recent price movement in BioHarvest Sciences Inc. (CNVCF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary Bioplant technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CNVCF overvalued or undervalued right now?
Determining whether BioHarvest Sciences Inc. (CNVCF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CNVCF?
Before investing in BioHarvest Sciences Inc. (CNVCF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-16.
- AI analysis is pending for CNVCF, which may provide additional insights.